APA (7th ed.) Citation

Heiblig, M., Gourguechon, C., Guilpain, P., Livideanu, C. B., Barete, S., Agopian, J., . . . Rossignol, J. (2023). Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients. Blood, 142(Supplement 1), 1837. https://doi.org/10.1182/blood-2023-185890

Chicago Style (17th ed.) Citation

Heiblig, Mael, et al. "Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients." Blood 142, no. Supplement 1 (2023): 1837. https://doi.org/10.1182/blood-2023-185890.

MLA (9th ed.) Citation

Heiblig, Mael, et al. "Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients." Blood, vol. 142, no. Supplement 1, 2023, p. 1837, https://doi.org/10.1182/blood-2023-185890.